Publications
5600 Results
- Journal / Conference
- ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
Development and Validation of a Risk Prediction Model for Acute Care Use among Advanced Cancer Patients on Clinical Trials
- Journal / Conference
- Lancet Haematology Sep 30:S2352-3026(24)00276-X. doi: 10.1016/S2352-3026(24)00276-X. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Lymphoma
Radiation Target Nomenclature for Lymphoma Trials: Consensus Recommendations from the National Clinical Trials Network Groups
- Journal / Conference
- Blood Sep 25:blood.2024025939. doi: 10.1182/blood.2024025939. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Myeloma
- PMID
- PMID39321347
- Study Number(s)
- S0777, S1211
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
- Journal / Conference
- New England Journal of Medicine Oct 17;391(15):1379-1389
- Year
- 2024
- Research Committee(s)
- Lymphoma
- PMID
- PMID39413375
- PMC
- PMC11488644
- Study Number(s)
- S1826
Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma
- Journal / Conference
- Journal for ImmunoTherapy of Cancer (JITC) Sep 28;12(9):e009128
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39343510
- PMC
- PMC11440191
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors
- Journal / Conference
- JAMA Network Open Oct 1;7(10):e2437871
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID39374015
- PMC
- PMC11581504
- Study Number(s)
- S1216
Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC)
- Journal / Conference
- Clinical Cancer Research Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39417692
- Study Number(s)
- S1609
SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
- Journal / Conference
- JCO Precision Oncology Nov:8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. 2024
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
DNA Damage Response Gene Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
- Journal / Conference
- ICTHIC Meeting (May 17-19, 2024, Bergamo, Italy)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Navigating the Interplay of Cancer, Hemostasis, and Thrombosis: Investigating Tissue Factor in Colorectal Cancer
- Journal / Conference
- Journal of Clinical Oncology Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Breast
- PMID
- PMID39621968
- Study Number(s)
- S1007, SWOG-8814